Skip to main navigation Skip to search Skip to main content

Amyloidosis

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The amyloidoses are protein-misfolding diseases caused by a precursor protein that undergoes a conformational change, which in turn triggers the formation of amyloid fibrils that damage different organs. Amyloidosis can be either localized or systemic. The systemic amyloidoses can be manifested clinically in many organs, most notably the heart, kidneys, liver, peripheral nerves, skin, gastrointestinal tract, and the microvasculature of the brain. Diagnosis can be confirmed by mass spectrometry or immunoelectron microscopy (for unequivocal amyloid typing) of a Congo red-positive tissue biopsy of clinically involved organs or surrogate tissue, such as subcutaneous fat pad or bone marrow. The amyloidoses are not common and their presenting symptoms may be missed or confused with other clinical entities. For light chain amyloidosis, current therapy produces response rates of about 70% and median survival upward of 5 years.

Original languageEnglish (US)
Title of host publicationGoldman-Cecil Medicine, 27th Edition
Subtitle of host publicationVolume 1-2
PublisherElsevier
Pages1305-1310.e1
Volume1
ISBN (Electronic)9780323930383
ISBN (Print)9780323930390
DOIs
StatePublished - Jan 1 2023

Keywords

  • amyloidosis
  • light chain
  • monoclonal immunoglobulin
  • nephrotic syndrome
  • restrictive cardiomyopathy
  • stem cell transplant

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Amyloidosis'. Together they form a unique fingerprint.

Cite this